Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“NLRP3 Inhibition in Atherosclerosis: Early Clinical Signal Beyond Lipids
Targeting residual inflammatory risk has become a central challenge in contemporary cardiovascular prevention, particularly in patients who achieve optimal LDL-C control yet remain at elevated risk.
Within this framework, the NLRP3 inflammasome has emerged as a pivotal upstream regulator of vascular inflammation, orchestrating the IL-1B-IL-6-CRP signaling cascade that drives plaque progression, instability, and eventual clinical events.
Early clinical evidence with the oral NLRP3 inhibitor VTX3232 provides a compelling proof-of-concept for this therapeutic strategy.
In a randomized, double-blind phase 2a trial involving individuals with obesity and heightened cardiometabolic risk, treatment with VTX3232 led to profound reductions in inflammatory biomarkers, including up to a ~78% decrease in hsCRP and significant suppression of IL-6 levels.
Notably, these anti-inflammatory effects occurred independently of weight loss, underscoring a mechanism distinct from metabolic modulation.
When combined with semaglutide, VTX3232 demonstrated additive reductions in hsCRP, IL-6, lipoprotein(a), and fibrinogen, suggesting a complementary role alongside established cardiometabolic therapies. These findings reinforce the concept of targeting inflammation as an orthogonal axis of risk reduction.
However, current evidence remains limited to biomarker modulation, with no demonstrated impact on hard cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality.
While mechanistically robust and clinically promising, the ultimate role of NLRP3 inhibition in atherosclerosis will depend on large-scale, event-driven trials.
Reference:
- Ventyx Biosciences. Phase 2a Study of VTX3232 in Cardiometabolic Risk (ACC 2026 Presentation);
- Molecular Metabolism (2025);
- Healio Cardiology News (2026).”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Apr 16, 2026, 06:40Susan Shea: Real-Time Platelet Function Assessment in Trauma Patients
-
Apr 16, 2026, 06:36Alan Nurden: Structural Complexity of Contact Sites within Platelet Aggregates
-
Apr 16, 2026, 06:29Aaron Rodriguez Calienes: Grateful to Receive 2nd Consecutive DeSousa Award in Stroke and Interventional Research
-
Apr 16, 2026, 06:24Paul Bolaji: A Growing Movement to Transform Stroke Care in Africa
-
Apr 16, 2026, 05:22Cedric Hermans: A Simple Way to Stay Updated in Haemophilia and von Willebrand Disease
-
Apr 16, 2026, 04:29Vijay Shah: Increasing Value of AI-Based Assessment in Cardiovascular Risk Prediction
-
Apr 16, 2026, 04:13Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
-
Apr 16, 2026, 04:11Paolo Zamboni: Enjoy the New Super Articles From Veins and Lymphatics Page Press
-
Apr 16, 2026, 04:03Platelet DGD – A Common But Underdiagnosed Bleeding Disorder – RPTH